Unusual patterns of igG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 459-467

  Yam, Karen K ^a   Gupta, Jyotsana ^a   Brewer, Angela ^a   Scheifele, David W ^b   Halperin, Scott ^c   Ward, Brian J ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA VACCINATION; PRIORITY JOURNAL; SERODIAGNOSIS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CANADA; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS;

EID: 84876468091     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00619-12     Document Type: Article

References (39)

1. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. 2007. Antigen sparing and crossreactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370:580-589.
2. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. 2008. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198:642-649.
3. Technical Advisory Group on Vaccine-Preventable Diseases. 2009. Final recommendations of pandemic influenza. Pan American Health Organization, Regional Office of the World Health Organization, Geneva, Switzerland. http://www.paho.org/english/ad/fch/im/PandemicFlu-TAGReco-Aug2009 -e.pdf.
4. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garcon N, Van MM. 2011. Adjuvant system AS03 containing alphatocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461-2473.
5. Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van MM. 2011. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31:443-454.
6. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. 2008. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665. doi:10.1371/journal.pone. 0001665.
7. GlaxoSmithKline, Inc. 2009. Arepanrix H1N1 (package insert). Glaxo-SmithKline, Inc., Mississauga, Ontario, Canada.
8. Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA. 2011. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr. Infect. Dis. J. 30:402-407.
9. World Health Organization. 2010. Serological diagnosis of influenza by microneutralization assay. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/gisrs-laboratory/2010-12-06 -serological-diagnosis- of-influenza-by-microneutralization-assay.pdf.
10. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. 1999. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis. 179:31-36.
11. Jefferis R. 2012. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526:159-166.
12. Hamilton RG, Mohan C. 2001. The human IgG subclasses. Calbiochem, Baltimore, MD.
13. El-Madhun AS, Cox RJ, Haaheim LR. 1999. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J. Infect. Dis. 180:1356-1360.
14. Ferrante A, Beard LJ, Feldman RG. 1990. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr. Infect. Dis. J. 9:S16-S24.
15. Wagner R, Gopfert C, Hammann J, Neumann B, Wood J, Newman R, Wallis C, Alex N, Pfleiderer M. 2012. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine 30:4113-4122.
16. Gordon CL, Johnson PD, Permezel M, Holmes NE, Gutteridge G, McDonald CF, Eisen DP, Stewardson AJ, Edington J, Charles PG, Crinis N, Black MJ, Torresi J, Grayson ML. 2010. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin. Infect. Dis. 50:672-678.
17. Hocart MJ, Mackenzie JS, Stewart GA. 1990. Serum IgG subclass responses of humans to inactivated and live influenza A vaccines compared to natural infections with influenza A. J. Med. Virol. 30:92-96.
18. McHeyzer-Williams LJ, McHeyzer-Williams MG. 2005. Antigenspecific memory B cell development. Annu. Rev. Immunol. 23:487-513.
19. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Jr, Wilson IA. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328:357-360.
20. Hamkar R, Jalilvand S, Mokhtari-Azad T, Nouri JK, Dahi-Far H, Soleimanjahi H, Nategh R. 2005. Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine. J. Virol. Methods 130: 59-65.
21. Fox JL, Hazell SL, Tobler LH, Busch MP. 2006. Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus. Clin. Vaccine Immunol. 13:33-36.
22. Prince HE, Yeh C, Lape-Nixon M. 2011. Utility of IgM/IgG ratio and IgG avidity for distinguishing primary and secondary dengue virus infections using sera collected more than 30 days after disease onset. Clin. Vaccine Immunol. 18:1951-1956.
23. Institut National de Santé Publique du Québec. 2010. Bilan épidémiologique de la pandeemie d'influenza A (H1N1). Government of Quebec, Montreal, Quebec, Canada. http://www.inspq.qc.ca/pdf/publications/ 1212 -BilanAH1N12009.pdf.
24. Influenza and Emerging Respiratory Pathogens Team. 2010. Pandemic influenzaA/H1N1virus(pH1N1)case surveillance update, British Columbia. BC Centre for Disease Control, Vancouver, British Columbia, Canada. http: //www.bccdc.ca/NR/rdonlyres/EB9B5651-1251-4E16-8AFE-D4819DADBE B2/0/BC-pH1N1-Surveillance-Update-2010Feb25.pdf.
25. Alberta Health and Wellness and Alberta Health Services. 2010. Pandemic H1N1 (2009): The Alberta experience. Government of Alberta, Calgary, Alberta, Canada. http://www.health.alberta.ca/documents/H1N1-Alberta-Experience-2010.pdf.
26. Department of Health Promotion and Protection and Department of Health. 2010. Nova Scotia's response to H1N1: Summary report. Government of Nova Scotia, Halifax, Nova Scotia, Canada. http://www.gov.ns.ca /hpp/publications/H1N1- Summary-Report.pdf.
27. Grilli EA, Davies JR, Smith AJ. 1986. Infection with influenza A H1N1. 1. Production and persistence of antibody. J. Hyg. (Lond.) 96:335-343.
28. Schild GC, Newman RW, McGregor IA, Williams K. 1977. The use of transportable single-radial-diffusion immunoplates in seroepidemiological studies of influenza in the Gambia: The occurrence and persistence of antibody to influenza A/Hong Kong/68 (H3N2) virus in selected inhabitants of two rural villages. Bull. World Health Organ. 55:3-13.
29. Skowronski DM, Hottes TS, De SG, Ward BJ, Janjua NZ, Sabaiduc S, Chan T, Petric M. 2011. Influenza Beta/Victoria antigen induces strong recall of Beta/Yamagata but lower Beta/Victoria response in children primed with two doses of Beta/Yamagata. Pediatr. Infect. Dis. J. 30:833-839.
30. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. 2012. Immune response following H1N1pdm09 vaccination: Differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J. Infect. Dis. 205:610-620.
31. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del GG, Rappuoli R, Golding H. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3:85ra48.
32. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. 2012. Waning antibody levels and avidity: Implications for MMR vaccine-induced protection. J. Infect. Dis. 206:1542-1548.
33. Marshall BC, Adler SP. 2003. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: A live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). Viral Immunol. 16:491-500.
34. Atrasheuskaya AV, Neverov AA, Rubin S, Ignatyev GM. 2006. Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine 24:1530-1536.
35. Hedman K, Hietala J, Tiilikainen A, Hartikainen-Sorri AL, Raiha K, Suni J, Vaananen P, Pietilainen M. 1989. Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing. J. Med. Virol. 27:293-298.
36. Lavoria MA, Di-Giacomo S, Bucafusco D, Franco-Mahecha OL, Perez-Filgueira DM, Capozzo AV. 2012. Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against foot-and-mouth disease virus in cattle. Vaccine 30: 6845-6850.
37. Bergen MJ, Pan CH, Greer CE, Legg HS, Polo JM, Griffin DE. 2010. Comparison of the immune responses induced by chimeric alphavirusvectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One 5:e10297. doi:10.1371/journal.pone.0010297.
38. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. 2007. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J. Infect. Dis. 196:1339-1345.
39. Mellander L, Bottiger M, Hanson LA, Taranger J, Carlsson B. 1993. Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Paediatr. 82:552-556.